SCHEDULE: FMR LLC Discloses 8.4% Stake in Arrivent Biopharma

FMR LLC and Abigail P. Johnson have reported an 8.4% beneficial ownership stake in Arrivent Biopharma Inc. as of September 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson have filed an Amendment No. 1 to Schedule 13G, disclosing their beneficial ownership in Arrivent Biopharma Inc.
• As of September 30, 2025, FMR LLC and Abigail P. Johnson beneficially own 3,407,549 shares of Arrivent Biopharma Inc. common stock.
• This ownership represents 8.4% of the total outstanding common stock of Arrivent Biopharma Inc.
• FMR LLC, a Delaware entity, holds sole voting power over 3,407,161 shares and sole dispositive power over 3,407,549 shares.
• Abigail P. Johnson, a U.S. citizen and a Director, Chairman, and CEO of FMR LLC, holds sole dispositive power over 3,407,549 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Select Biotechnology Portfolio is known to have an interest of 2,346,517 shares, or 5.8% of the total outstanding common stock, as of September 30, 2025.
• Fidelity Management & Research Company LLC (an investment adviser) and Fidelity Management Trust Company (a bank) are identified as relevant entities within FMR LLC's structure.

Sentiment

Score: 7

Explanation: The disclosure of a significant 8.4% beneficial ownership by a major institutional investor like FMR LLC is generally a positive signal, indicating confidence in the company. While it's a passive stake, it suggests a favorable view from a sophisticated market participant.

Positives

• A significant institutional investor like FMR LLC taking an 8.4% stake can signal confidence in Arrivent Biopharma Inc.'s long-term prospects.
• The disclosure of a substantial holding by a reputable investment firm may attract further investor interest and potentially improve market liquidity.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Arrivent Biopharma Inc.'s future performance or FMR LLC's future investment intentions beyond the ordinary course of business.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major institutional asset manager, FMR LLC (Fidelity), in Arrivent Biopharma Inc. Such filings are common for large investment firms that cross a 5% ownership threshold in publicly traded companies. For the biopharma sector, institutional backing from firms like Fidelity can be a positive signal, suggesting that the company's pipeline or market position is viewed favorably by sophisticated investors, even if the investment is passive.

Comparison to Industry Standards

• FMR LLC, through its various funds and entities, is one of the largest asset managers globally, frequently holding significant stakes (above 5%) in numerous public companies across various sectors, including biotechnology.
• An 8.4% stake is a substantial passive position for an institutional investor, indicating a meaningful allocation within their portfolio, comparable to other significant institutional holdings in emerging or growth-oriented biopharma companies.
• The disclosure of Select Biotechnology Portfolio holding 5.8% within the broader FMR LLC ownership structure highlights a focused investment within a specialized fund, which is a common strategy for large asset managers to target specific industry segments.

Stakeholder Impact

• Shareholders: Existing shareholders may view the significant institutional investment as a vote of confidence, potentially leading to increased share price stability or appreciation. It also indicates strong institutional interest in the company.
• Management: Management may feel validated by the institutional backing, which could support their strategic direction and operational plans.
• Potential Investors: The presence of a major institutional investor like FMR LLC can make Arrivent Biopharma Inc. more attractive to other institutional and retail investors.

Next Steps

• Arrivent Biopharma Inc. will continue its operations and strategic initiatives.
• FMR LLC may adjust its holdings in Arrivent Biopharma Inc. in the future, which would be disclosed in subsequent Schedule 13G amendments or a Schedule 13D if the intent becomes active.

Key Dates

Recommendation

The filing indicates a significant institutional stake by FMR LLC, which is generally a positive signal of confidence. However, a Schedule 13G is a passive ownership disclosure and does not provide new operational or financial performance data for Arrivent Biopharma Inc. While institutional backing is favorable, it doesn't inherently change the fundamental investment thesis for existing holders. For new investors, it might warrant further due diligence, but without additional company-specific news, a 'hold' recommendation is appropriate for existing positions, acknowledging the positive institutional interest.

Keywords

Arrivent Biopharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biopharma, Investment Management, Fidelity